Chengdu Kanghong Pharmaceutical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Chengdu Kanghong Pharmaceutical Group şirketinin toplam hissedar öz sermayesi CN¥8.4B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥9.2B ve CN¥778.2M dir. Chengdu Kanghong Pharmaceutical Group 'in FAVÖK'ü CN¥1.3B faiz karşılama oranı -12.2 dur. Şirketin CN¥5.5B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-12.2x
Nakit	CN¥5.55b
Eşitlik	CN¥8.43b
Toplam yükümlülükler	CN¥778.25m
Toplam varlıklar	CN¥9.21b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 002773 'nin kısa vadeli varlıkları ( CN¥6.2B ) kısa vadeli yükümlülüklerini ( CN¥735.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 002773 şirketinin kısa vadeli varlıkları ( CN¥6.2B ) uzun vadeli yükümlülüklerini ( CN¥42.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 002773 borçsuzdur.

Borcun Azaltılması: 002773 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 002773 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 002773 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Chengdu Kanghong Pharmaceutical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.33 in 3Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.27 in 2Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 23, 2024

Dividend increased to CN¥0.38

Investor sentiment improves as stock rises 19%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 1Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 19%

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.24 in 3Q 2022)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.26 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023

Investor sentiment improves as stock rises 15%

Insufficient new directors

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2021)

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Cash Dividend for A Shares for the Year 2021, Payment date is 08 June 2022

Chengdu Kanghong Pharmaceutical Group Co. Ltd. Approves Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2021)

High number of new directors

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.28 in 3Q 2020)

High number of new directors

Second quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.18 in 2Q 2020)

Chengdu Kanghong Pharmaceuticals Group Co., Proposes Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.20 in 1Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥35.28

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.82 in FY 2019)

Revenue misses expectations

Chengdu Kanghong Pharmaceutical Group Receives Special Protocol Assessments from the Food and Drug Administration for Three New Indications for Its Biologic Drug Conbercept

New 90-day low: CN¥35.44

New 90-day low: CN¥39.81

Investor sentiment improved over the past week

New 90-day high: CN¥47.89

Chengdu Kanghong Pharmaceuticals Group Co., Ltd Announces Completion 36-Week Primary Endpoint Visits of Phase Iii Trial of Conbercept

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥42.93

New 90-day high - CN¥51.18

Earnings released

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin